This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

In one aspect, the invention relates to compounds having the formula I: ##STR00001##
where R.sup.1-R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

In one aspect, the invention relates to compounds having the formula I: ##STR00001##
where R.sup.1-R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

The present disclosure generally relates to classes of compounds that bind the chromo-barrel domain of AT-rich interactive domain 4B (ARID4B). In some aspects, the compounds are of the Formula (II) as described herein, or a diamine composite thereof as set forth in Formula III herein. In some aspects, the compound is selected from compounds 1a, 1b, 1c, 1d, 1e, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 2j, (as described herein) or combinations thereof. The present disclosure further considers administration of the compounds to target ARID4B in cells and for the treatment of cancerous breast tissue cells.

In one aspect, the invention relates to compounds having the formula:

##STR00001##

where R.sup.1-R.sup.6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

A compound of general formula (I)

##STR00001## or a pharmaceutically acceptable salt and/or solvate thereof, and the process for manufacturing the compound of general formula (I). Also, a pharmaceutical composition that includes a compound of general formula (I), and the use of compounds of general formula (I) as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological disorders.